Number of participants
|
12
|
8
| |
Female, N (%)
|
12 (100%)
|
8 (100%)
|
> 0.999
|
Age in years
|
21 (21–24)
|
22 (20–23)
|
0.917
|
Fiebig stages I–II at diagnosis, N (%)a
|
11 (92%)
|
8 (100%)
|
> 0.999
|
Fiebig stages I–II at ART initiation, N (%)
|
N/A
|
8 (100%)
|
N/A
|
Days from detection to ART initiation and range
|
N/A
|
1 (1–2)
|
N/A
|
Nadir CD4+ T cell countsb (cells/μL)
|
329 (233–458)
|
840 (623–1008)
|
< 0.001
|
Peak viral load (log10 RNA copies/mL)
|
7.08 (6.93–7.75)
|
4.26 (3.45–5.13)
|
< 0.001
|
Days from detection to viral suppression and range
|
N/A
|
23 (7–63)
|
N/A
|
Set point CD4+ T cell counts (cells/μL)c
|
583 (555–630)
|
N/A
|
N/A
|
Set point viral load (log10 RNA copies/mL)c
|
4.74 (4.11–5.36)
|
N/A
|
N/A
|